Table 9 Bayesian method estimates of indirect probabilities of passing different visual acuity thresholds at month 1 for patients with BRVO on scale of GENEVA trial
Improvement or worsening at Month 1 | Probability for Group§ (95% CrI) | Relative risk* (95% CrI) | |
|---|---|---|---|
Ranibizumab | Dexamethasone | ||
Gain ≥15 letters | 0.260 (0.140,0.414) | 0.213 (0.168,0.261) | 0.82 (0.45,1.47) |
Gain ≥5 letters and <15 letters | 0.453 (0.317,0.593) | 0.470 (0.413,0.526) | 1.04 (0.74,1.45) |
Loss <5 letters and gain <5 letters | 0.264 (0.163,0.385) | 0.257 (0.209,0.308) | 0.97 (0.61,1.57) |
Loss ≥5 letters and <15 letters | 0.018 (0.002,0.055) | 0.057 (0.034,0.086) | 3.27 (0.60,17.70) |
Loss ≥15 letters | 0.005 (0.000,0.025) | 0.003 (0.000,0.012) | 0.62 (0.02,18.40) |